表紙
市場調查報告書

酪胺酸蛋白激酶JAK2:開發中產品分析

Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 367827
出版日期 內容資訊 英文 203 Pages
訂單完成後即時交付
價格
酪胺酸蛋白激酶JAK2:開發中產品分析 Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 203 Pages
簡介

本報告提供以酪胺酸蛋白激酶JAK2為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶JAK2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Aerie Pharmaceuticals, Inc.
  • Aptose Biosciences Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Celon Pharma Sp. z o.o.
  • Concert Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
  • 第一三共
  • Eli Lilly and Company
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • 日本新藥
  • Novartis AG
  • SOM Innovation Biotech SL
  • Theravance Biopharma, Inc.
  • Tolero Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2527TDB

Summary:

According to the recently published report 'Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020'; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 34 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

The report 'Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020' outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4, 7, 3, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Infectious Disease, Gastrointestinal, Hematological Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders and Women's Health which include indications Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Atopic Dermatitis (Atopic Eczema), Coronavirus Disease 2019 (COVID-19), Alopecia Areata, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Graft Versus Host Disease (GVHD), Inflammation, Rheumatoid Arthritis, Chronic Myelomonocytic Leukemia (CMML), Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Polycythemia Vera, Primary Myelofibrosis, Psoriasis, Acute Lung Injury, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Breast Hyperplasia, Bronchiolitis Obliterans, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Cytokine Release Syndrome (Cytokine Storm), Dermatitis (Eczema), Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Epstein-Barr Virus (HHV-4) Infections, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Glaucoma, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Juvenile Arthritis, Laryngeal Cancer, Leukemia, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Myeloproliferative Disorders, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pneumonia, Polymyalgia Rheumatica (PMR), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Proliferative Diabetic Retinopathy (PDR), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1)
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Adastra Pharmaceuticals Inc, H2 2020
  • Pipeline by Aerie Pharmaceuticals Inc, H2 2020
  • Pipeline by AstraZeneca Plc, H2 2020
  • Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Dormant Products, H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020